Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
05/25/2020 05/26/2020 05/27/2020 05/28/2020 05/29/2020 Date
43.88(c) 43.06(c) 42.36(c) 43.15(c) 43.2(c) Last
1 107 735 1 823 833 2 648 069 1 866 575 3 107 182 Volume
+1.88% -1.87% -1.63% +1.86% +0.12% Change
More quotes
Financials
Sales 2020 37 062 M 41 164 M 41 164 M
Net income 2020 1 771 M 1 967 M 1 967 M
Net Debt 2020 23 216 M 25 786 M 25 786 M
P/E ratio 2020 13,5x
Yield 2020 1,93%
Sales 2021 39 190 M 43 528 M 43 528 M
Net income 2021 2 069 M 2 298 M 2 298 M
Net Debt 2021 21 692 M 24 093 M 24 093 M
P/E ratio 2021 11,7x
Yield 2021 2,07%
Capitalization 24 080 M 26 771 M 26 746 M
EV / Sales 2020 1,28x
EV / Sales 2021 1,17x
Nbr of Employees 299 594
Free-Float 72,1%
More Financials
Company
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (49.2%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (31.4%;... 
More about the company
Surperformance© ratings of Fresenius SE & Co. KGaA
Trading Rating : Investor Rating :
More Ratings
Latest news on FRESENIUS SE & CO. KGAA
05/29FRESENIUS : Buys Hospital in Germany
DJ
05/29FRESENIUS : Helios acquires hospital in western Germany
PU
05/28FRESENIUS : FDA accepts for review Fresenius Kabi's first biosimilar regulatory ..
AQ
05/28FRESENIUS : Kabi Enters Marketing Agreement With Germany's Medac
DJ
05/28FRESENIUS : Kabi enters marketing agreement for biosimilar product
PU
05/27FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
05/27FRESENIUS KABI : FDA Accepts BLA for Neulasta Biosimilar
DJ
05/27FRESENIUS : Kabi's regulatory submission for pegfilgrastim biosimilar accepted f..
PU
05/25FRESENIUS : Kabi's regulatory submission for pegfilgrastim biosimilar accepted f..
AQ
05/25FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
05/22FRESENIUS : Kabi's regulatory submission for pegfilgrastim biosimilar accepted f..
PU
05/22FMC FRESENIUS MEDICAL CARE AG & CO K : Credit Suisse gives a Neutral rating
MD
05/22FRESENIUS SE : Credit Suisse remains Neutral
MD
05/21FRESENIUS MEDICAL CARE : Confirms Illegal Publication of Patient Data in Serbia
DJ
05/20FMC FRESENIUS MEDICAL CARE AG & CO K : Goldman Sachs maintains a Buy rating
MD
More news
News in other languages on FRESENIUS SE & CO. KGAA
05/29DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 29.05.2020 - 15.15 Uhr
05/29KRANKENHÄUSER :  Staatliche Hilfen in Corona-Krise reichen nicht
05/29FRESENIUS : acquisition d'un hôpital à Bonn
05/29Malteser Orden verkauft Bonner Klinik an Fresenius
05/29FRESENIUS : Buys Hospital in Germany
More news
Analyst Recommendations on FRESENIUS SE & CO. KGAA
More recommendations
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 50,88 €
Last Close Price 43,20 €
Spread / Highest target 53,5%
Spread / Average Target 17,8%
Spread / Lowest Target -58,2%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors